Exelixis Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (54)

Latest Posts

About This Stock More About This Stock
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Article By: Zacks Investment Research
Saturday, March 9, 2024 4:00 PM EDT
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the year.
In this article: EXEL, EXAS, ASND, LEGN, MOR
Read
3 Attractive Medical Stocks To Buy After Earnings
Article By: Zacks Investment Research
Thursday, February 8, 2024 7:50 PM EDT
Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare stocks that investors will want to consider
In this article: MCK, EXEL, EHC
Read
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
Article By: ChinaBio® Today
Saturday, September 16, 2023 12:59 PM EDT
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis.
In this article: SHPMF, EXEL, TSVT, SRNEQ
Read
This Biotech Looks Good With Increased M&A Activity
Article By: InvestorsAlley
Friday, May 20, 2022 3:49 AM EDT
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
In this article: ACAD, EXEL, XBI
Read
Early Monday Report - More Moves Out Of China
Article By: Vivian Lewis
Sunday, January 9, 2022 7:24 PM EDT
Before it even turned Monday in the West, China insurers were feeling the heat.
In this article: BIIB, LLY, TSM, ALKS, EXEL, CGEN
Read

Latest Tweets for $EXEL

No tweets yet!

PARTNER HEADLINES